MCID: HRN003
MIFTS: 41

Heroin Dependence

Categories: Mental diseases

Aliases & Classifications for Heroin Dependence

MalaCards integrated aliases for Heroin Dependence:

Name: Heroin Dependence 12 44 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9976
MeSH 44 D006556
NCIt 50 C34694
UMLS 72 C0019337

Summaries for Heroin Dependence

Disease Ontology : 12 An opiate dependence that involves the continued use of heroin despite problems related to use of the substance.

MalaCards based summary : Heroin Dependence is related to opioid addiction and withdrawal disorder. An important gene associated with Heroin Dependence is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Circadian entrainment and Amphetamine addiction. The drugs Dopamine and Buspirone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and pituitary, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 75 Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or... more...

Related Diseases for Heroin Dependence

Diseases related to Heroin Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 opioid addiction 30.5 OPRM1 OPRD1 DRD2
2 withdrawal disorder 30.4 PDYN OPRM1
3 morphine dependence 30.4 OPRM1 OPRD1
4 antisocial personality disorder 30.4 SLC6A3 DRD2 ANKK1
5 opiate dependence 30.4 PDYN OPRM1 OPRD1 DRD2
6 neonatal abstinence syndrome 30.3 OPRM1 OPRD1
7 personality disorder 30.2 SLC6A3 DRD4 DRD2 ANKK1
8 major depressive disorder 30.2 SLC6A3 DRD4 DRD2
9 substance abuse 30.1 SLC6A3 MIAT DRD4 DRD2
10 psychotic disorder 30.0 SLC6A3 DRD4 DRD2
11 conduct disorder 29.7 SLC6A3 DRD4 DRD2
12 substance dependence 29.7 SLC6A3 OPRM1 OPRD1 DRD4 DRD2
13 tobacco addiction 29.6 SLC6A3 OPRM1 DRD2 ANKK1
14 drug dependence 29.3 PDYN OPRM1 OPRD1 DRD2 ANKK1
15 cocaine dependence 29.2 SLC6A3 PDYN OPRM1 OPRD1 DRD2
16 attention deficit-hyperactivity disorder 29.2 SLC6A3 OPRM1 DRD4 DRD2 ANKK1
17 disease of mental health 28.5 SLC6A3 PDYN OPRM1 DRD4 DRD2
18 alcohol dependence 28.3 SLC6A3 PDYN OPRM1 OPRD1 DRD4 DRD2
19 alcohol-induced mental disorder 10.4 SLC6A3 DRD2
20 alcoholic psychosis 10.4 SLC6A3 DRD2
21 striatonigral degeneration 10.4 SLC6A3 DRD2
22 delusional disorder 10.3 DRD4 DRD2
23 arterial thoracic outlet syndrome 10.3
24 stuttering 10.3 SLC6A3 DRD2
25 borderline personality disorder 10.3
26 taqi polymorphism 10.3 DRD2 ANKK1
27 alexithymia 10.2 DRD2 ANKK1
28 cocaine abuse 10.2 SLC6A3 DRD2
29 post-traumatic stress disorder 10.2
30 acute stress disorder 10.2
31 migraine without aura 10.2 DRD4 DRD2
32 sexual disorder 10.2
33 depression 10.2
34 mental depression 10.1
35 restless legs syndrome 10.1 SLC6A3 DRD2
36 separation anxiety disorder 10.1 SLC6A3 OPRM1 DRD4
37 pathological gambling 10.1 SLC6A3 DRD4 DRD2
38 oppositional defiant disorder 10.1 SLC6A3 DRD4 DRD2
39 avoidant personality disorder 10.1
40 mood disorder 10.1
41 tic disorder 10.1 SLC6A3 DRD4 DRD2
42 pain agnosia 10.1 PDYN OPRM1
43 gilles de la tourette syndrome 10.0 SLC6A3 DRD4 DRD2
44 agnosia 10.0 PDYN OPRM1
45 major affective disorder 8 10.0
46 major affective disorder 9 10.0
47 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
48 bipolar disorder 10.0
49 multiple system atrophy 1 10.0 SLC6A3 DRD2
50 impulse control disorder 10.0 DRD4 DRD2 ANKK1

Graphical network of the top 20 diseases related to Heroin Dependence:



Diseases related to Heroin Dependence

Symptoms & Phenotypes for Heroin Dependence

MGI Mouse Phenotypes related to Heroin Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 AUTS2 DRD2 DRD4 OPRD1 OPRM1 PDYN
2 nervous system MP:0003631 9.5 AUTS2 DRD2 DRD4 OPRD1 OPRM1 PDYN
3 no phenotypic analysis MP:0003012 9.02 AUTS2 DRD2 OPRD1 OPRM1 PDYN

Drugs & Therapeutics for Heroin Dependence

Drugs for Heroin Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
4
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Methadone Approved, Illicit Phase 4 76-99-3 4095
7
Ethanol Approved Phase 4 64-17-5 702
8 Tranquilizing Agents Phase 4
9 Anti-Anxiety Agents Phase 4
10 Serotonin Receptor Agonists Phase 4
11 Serotonin Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Analgesics Phase 4
14 Narcotics Phase 4
15 Central Nervous System Depressants Phase 4
16 Narcotic Antagonists Phase 4
17 Peripheral Nervous System Agents Phase 4
18 Analgesics, Opioid Phase 4
19
Heroin Phase 4 5462328
20 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
21 Respiratory System Agents Phase 4
22 Antitussive Agents Phase 4
23
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
24
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
25
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
26
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
27
Hydromorphone Approved, Illicit Phase 3 466-99-9 5284570
28
Clonidine Approved Phase 3 4205-90-7 2803
29
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
30 Paliperidone Palmitate Phase 3
31 Dopamine Antagonists Phase 3
32 Antipsychotic Agents Phase 3
33 Dopamine D2 Receptor Antagonists Phase 3
34 Anti-Bacterial Agents Phase 3
35 Buprenorphine, Naloxone Drug Combination Phase 3
36 Neurotransmitter Agents Phase 2, Phase 3
37 Antihypertensive Agents Phase 3
38 Dopamine Agents Phase 2, Phase 3
39 Adrenergic alpha-2 Receptor Agonists Phase 3
40 Adrenergic Agonists Phase 3
41 Adrenergic alpha-Agonists Phase 3
42 Sympatholytics Phase 3
43 Excitatory Amino Acid Antagonists Phase 2, Phase 3
44 Excitatory Amino Acids Phase 2, Phase 3
45 Antiparkinson Agents Phase 2, Phase 3
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
47
Oxycodone Approved, Illicit, Investigational Phase 2 76-42-6 5284603
48
Mirtazapine Approved Phase 2 61337-67-5, 85650-52-8 4205
49
Histamine Approved, Investigational Phase 2 51-45-6 774
50
Methamphetamine Approved, Illicit Phase 2 537-46-2 10836

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
2 Graded Strategy for Pharmacological Treatment of Heroin Dependence Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
3 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
5 Effects of Buspirone in Withdrawal From Opiates Completed NCT00326235 Phase 4 Buspirone
6 Biomarkers of Disease and Response to Treatment in Opioid Addiction Active, not recruiting NCT02324725 Phase 4 Naltrexone
7 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Active, not recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
8 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence Unknown status NCT02541513 Phase 3 paliparidone
9 Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
10 An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS) Unknown status NCT02541500 Phase 3 Minocycline
11 CS1008 A&B Eff/Safety Trial of BUP/NX for the Treatment of Opiate Dependence Completed NCT00015171 Phase 3 Buprenorphine/naloxone
12 Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations Completed NCT00000302 Phase 3 Buprenorphine
13 Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification Completed NCT00032968 Phase 3 Buprenorphine/naloxone
14 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification Completed NCT00032955 Phase 3 Buprenorphine/naloxone
15 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial of At-Home Versus In-Office Buprenorphine Induction Completed NCT00684554 Phase 2, Phase 3 Buprenorphine
16 Directly Administered vs. Self-administered Antiretroviral Therapy in Methadone Clinics Completed NCT00279110 Phase 2, Phase 3
17 Methadone Maintenance for Prisoners Completed NCT00378079 Phase 3 Counseling + Transfer;Counseling + Methadone
18 Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial Completed NCT00577408 Phase 3 depot naltrexone;Oral Naltrexone
19 Reinforcing Effects of Intranasal Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intranasal Drug Users Completed NCT01760473 Phase 3 Intranasal challenge drug
20 Addiction Treatment in Russia: Oral and Depot Naltrexone Completed NCT00218426 Phase 2, Phase 3 naltrexone implant;oral naltrexone;oral placebo naltrexone;placebo implant
21 Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence Completed NCT00678418 Phase 3 VIVITROL® 380 mg;Placebo
22 Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence Completed NCT00476242 Phase 2, Phase 3 Vivitrol;memantine
23 Buprenorphine for Prisoners Completed NCT00574067 Phase 3 Buprenorphine +OTP;Buprenorphine +CHC;Counseling +OTP;Counseling +CHC
24 SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies Completed NCT01447212 Phase 3 Hydromorphone, Injectable;Diacetylmorphine, injectable;Hydromorphone, liquid oral;Diacetylmorphine, liquid oral
25 Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals Recruiting NCT03711318 Phase 3 Buprenorphine/naloxone
26 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Active, not recruiting NCT02774954 Phase 3
27 Evaluating the Role of Directly Administered Antiretroviral Therapy (DAART) in Conjunction With Opiate Substitution in Delivery of Highly Active Antiretroviral Therapy to HIV-1-infected Injecting Drug Users (IDUs) in Chennai, India Withdrawn NCT00709007 Phase 2, Phase 3
28 A Stage 1 Study of Community Reinforcement and Family Training for Treatment Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
29 Opioid Maintenance: Optimum Stabilization and Withdrawal Completed NCT00218127 Phase 2 Levoacetyl Methadol;Levoacetyl Methadol;Levoacetyl Methadol
30 Treatment Efficacy for Drug Abuse and AIDS Prevention Completed NCT00000211 Phase 2 Buprenorphine
31 Treatment Efficacy for Drug Abuse and AIDS Prevention Completed NCT00000210 Phase 2 Buprenorphine
32 A Laboratory Model for Heroin Abuse Medications Completed NCT00000273 Phase 2 opiates
33 Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Completed NCT01863251 Phase 2 Atomoxetine
34 Effects of Dynorphin 1-13 on Heroin Addiction Completed NCT00000244 Phase 2 Dynorphin 1 - 13
35 Study Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Completed NCT00332228 Phase 2 depot naltrexone;BNT
36 Opiate Dependence: Combined Naltrexone/Behavior Therapy Completed NCT00238914 Phase 2 Naltrexone
37 Heroin Addiction Treatment: Naltrexone and Adrenergic Agents Completed NCT00142948 Phase 2 Naltrexone;Placebo
38 Place of Low-Dose Naltrexone in Opiate Detoxification Completed NCT00135759 Phase 2 Naltrexone;Placebo comparator;naltrexone;naltrexone
39 Pilot Trial of a Therapeutic Interactive Voice Response System for Buprenorphine Maintenance: The Recovery Line Support System Completed NCT01315184 Phase 2
40 Transdermal Electroacupuncture for Opioid Detoxification Completed NCT00742170 Phase 1, Phase 2
41 Clinical Efficacy and Serum Proteomic Profiling of Traditional Chinese Medicine, Suan-Zao-Ren Tang, for Sleep Disturbance During Methadone Maintenance: Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01913418 Phase 2 Suan-Zao-Ren Tang;Suan-Zao-Ren Tang placebo
42 HIV Risk Reduction and Drug Abuse Treatment in Malaysia Completed NCT00383045 Phase 2 Buprenorphine/Subutex;Naltrexone
43 Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors Completed NCT00497081 Phase 2 mirtazapine;placebo
44 Effects of Pioglitazone, a PPARγ Agonist, on the Abuse Liability of Heroin and of Nicotine Terminated NCT01395797 Phase 1, Phase 2 PIO;Placebo
45 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 Withdrawn NCT00000331 Phase 2 Test Drug;Placebo Drug
46 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 Withdrawn NCT00000330 Phase 2 Opioid-Related Disorders
47 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1(1) Withdrawn NCT00000326 Phase 2 Heroin Dependence
48 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 Withdrawn NCT00000329 Phase 2 Opioid-Related Disorders
49 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III Withdrawn NCT00000328 Phase 2 Opioid-Related Disorders
50 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) Withdrawn NCT00000327 Phase 2 Heroin Dependence

Search NIH Clinical Center for Heroin Dependence

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Buprenorphine
Buprenorphine hydrochloride

Cochrane evidence based reviews: heroin dependence

Genetic Tests for Heroin Dependence

Anatomical Context for Heroin Dependence

MalaCards organs/tissues related to Heroin Dependence:

41
Testes, Brain, Pituitary, Cortex, Bone, Liver, Eye

Publications for Heroin Dependence

Articles related to Heroin Dependence:

(show top 50) (show all 611)
# Title Authors PMID Year
1
Contribution of the Visante® OCT and B-scan ultrasound in the diagnosis and follow up of a topiramate-induced bilateral ciliochoroidal effusion syndrome. 38
30738599 2019
2
Rumination and problematic substance use among individuals with a long-term history of illicit drug use. 38
31404848 2019
3
Atypical frontal midline theta activity during cognitive control in heroin addicts. 38
31283705 2019
4
Evaluation of a Pilot Intervention to Reduce Mental Health and Addiction Stigma in Primary Care Settings. 38
31317439 2019
5
Direct and indirect associations between perception of childhood trauma and suicidal ideation through emotion dysregulation in males who use heroin. 38
31233952 2019
6
Effects of childhood emotional maltreatment on depressive symptoms through emotion dysregulation in treatment-seeking patients with heroin-dependence. 38
31252238 2019
7
Abstinence Following a Motivation-Skill-Desensitization-Mental Energy Intervention for Heroin Dependence: A Three-year Follow-up Result of a Randomized Controlled Trial. 38
31209821 2019
8
Characterization of DSM-IV Opioid Dependence Among Individuals of European Ancestry. 38
31250797 2019
9
VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence. 38
30983500 2019
10
The Case against Forced Methadone Detox in the US Prisons. 38
30891098 2019
11
Heroin addiction engages negative emotional learning brain circuits in rats. 38
30913040 2019
12
Qualitative review and quantitative effect size meta-analyses in brain regions identified by cue-reactivity addiction studies. 38
30816782 2019
13
OPRD1 gene affects disease vulnerability and environmental stress in patients with heroin dependence in Han Chinese. 38
30171993 2019
14
Curb Heroin In Plants (C.H.I.P.): Revisiting a Mid-1970s Intervention Into Workplace Heroin Addiction Created and Led by Detroit Autoworkers. 38
30676794 2019
15
Association of CamK2A genetic variants with transition time from occasional to regular heroin use in a sample of heroin-dependent individuals. 38
30260900 2019
16
61 Heroin Dependence as an Enantiopathy to Quetiapine-Induced Restless Leg Syndrome. 38
30859982 2019
17
The role of emotion dysregulation in the relation of childhood trauma to heroin craving in individuals with heroin dependence. 38
30634108 2019
18
Metabolism and metabolomics of opiates: A long way of forensic implications to unravel. 38
30621882 2019
19
Support vector machine-based multivariate pattern classification of methamphetamine dependence using arterial spin labeling. 38
30623517 2019
20
The Effects of Oxytocin on Withdrawal, Craving and Stress Response in Heroin-Dependent Patients: A Randomized, Double-Blind Clinical Trial. 38
30630161 2019
21
Treatment of an HIV-affected adolescent with heroin dependence in a low-income country: A clinical case study from Zambia. 38
30505923 2018
22
Heroin Addiction in Serbian Patients With Tourette Syndrome. 38
30395551 2018
23
Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. 38
30107320 2018
24
GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence. 38
30060048 2018
25
Genetic association analyses and meta-analysis of Dynorphin-Kappa Opioid system potential functional variants with heroin dependence. 38
30138645 2018
26
NGF gene polymorphisms are not associated with heroin dependence in a Taiwanese male population. 38
30070410 2018
27
When is coercive methadone therapy justified? 38
29883516 2018
28
Re-evaluation of the KMSK scales, rapid dimensional measures of self-exposure to specific drugs: Gender-specific features. 38
30041093 2018
29
Genetic polymorphisms of FADS1, FADS2, and FADS3 and fatty acid profiles in subjects received methadone maintenance therapy. 38
28161285 2018
30
Risk of Heroin Dependence in Newly Incident Heroin Users. 38
29847618 2018
31
Association between stress pathway gene (CRHR1⧹CRHBP) polymorphisms and heroin dependence. 38
29853227 2018
32
Altered gray matter volume and disrupted functional connectivity of dorsolateral prefrontal cortex in men with heroin dependence. 38
29582514 2018
33
A 35.8 kilobases haplotype spanning ANKK1 and DRD2 is associated with heroin dependence in Han Chinese males. 38
29550268 2018
34
Improving recruitment to pharmacological trials for illicit opioid use: findings from a qualitative focus group study. 38
29356208 2018
35
The long-term impact of post traumatic stress disorder on recovery from heroin dependence. 38
29706174 2018
36
Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months. 38
29728088 2018
37
Increased Neutrophil-lymphocyte and Platelet-lymphocyte Ratios in Male Heroin Addicts: A Prospective Controlled Study. 38
29739133 2018
38
Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam. 38
29471930 2018
39
Opioid Receptors Gene Polymorphism and Heroin Dependence in Iran. 38
29967669 2018
40
Evaluation of prodynorphin gene polymorphisms and their association with heroin addiction in a sample of the southeast Iranian population. 38
29911117 2018
41
Inflammatory chemokine eotaxin-1 is correlated with age in heroin dependent patients under methadone maintenance therapy. 38
29222992 2018
42
Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. 38
29247974 2018
43
Prevalence of Deliberate Self-harm Among Chinese Patients With Heroin Dependence: A Meta-Analysis. 38
30072926 2018
44
Decision-Making Under Risk, but Not Under Ambiguity, Predicts Pathological Gambling in Discrete Types of Abstinent Substance Users. 38
29922190 2018
45
Health Related Quality of Life in Individuals Transferred from a Needle Exchange Program and Starting Opioid Agonist Treatment. 38
30662785 2018
46
"Why Am I the Way I Am?" Narrative Work in the Context of Stigmatized Identities. 38
28901830 2017
47
Traditional Chinese medicine-facilitated treatments may relieve anxiety symptoms during drug switching from methadone to buprenorphine/naloxone for treating opioid dependence. 38
29127135 2017
48
Gender differences in substance use patterns and disorders among an Iranian patient sample receiving methadone maintenance treatment. 38
29038721 2017
49
DRD2 and ANKK1 genes associate with late-onset heroin dependence in men. 38
28854834 2017
50
Expression of brain-derived neurotrophic factors, neurotrophin-3, and neurotrophin-4 in the nucleus accumbens during heroin dependency and withdrawal. 38
28538519 2017

Variations for Heroin Dependence

Expression for Heroin Dependence

Search GEO for disease gene expression data for Heroin Dependence.

Pathways for Heroin Dependence

Pathways related to Heroin Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.13 SLC6A3 OPRM1 DRD4 DRD2
2
Show member pathways
10.87 SLC6A3 PDYN DRD2

GO Terms for Heroin Dependence

Cellular components related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.85 SLC6A3 OPRM1 OPRD1 DRD4 DRD2
2 dendrite GO:0030425 9.67 PDYN OPRM1 DRD4 DRD2
3 membrane raft GO:0045121 9.61 SLC6A3 OPRM1 OPRD1
4 axon terminus GO:0043679 9.43 PDYN OPRD1 DRD2
5 dendrite membrane GO:0032590 9.4 OPRM1 OPRD1
6 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A3 OPRM1 DRD2
7 dopaminergic synapse GO:0098691 9.32 SLC6A3 DRD2
8 spine apparatus GO:0097444 8.96 OPRM1 OPRD1
9 integral component of presynaptic membrane GO:0099056 8.92 SLC6A3 OPRM1 OPRD1 DRD2

Biological processes related to Heroin Dependence according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.99 PDYN OPRM1 OPRD1 DRD4 DRD2
2 response to ethanol GO:0045471 9.7 SLC6A3 OPRM1 DRD2
3 neuropeptide signaling pathway GO:0007218 9.69 PDYN OPRM1 OPRD1
4 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.65 OPRM1 OPRD1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.65 OPRM1 OPRD1
6 adult locomotory behavior GO:0008344 9.64 OPRD1 DRD4
7 response to nicotine GO:0035094 9.64 SLC6A3 DRD2
8 positive regulation of multicellular organism growth GO:0040018 9.63 SLC6A3 DRD2
9 response to amphetamine GO:0001975 9.63 DRD4 DRD2
10 locomotory behavior GO:0007626 9.63 SLC6A3 OPRM1 DRD2
11 regulation of sensory perception of pain GO:0051930 9.62 OPRM1 OPRD1
12 response to morphine GO:0043278 9.62 OPRM1 DRD2
13 positive regulation of neurogenesis GO:0050769 9.61 OPRM1 DRD2
14 eating behavior GO:0042755 9.61 OPRM1 OPRD1
15 arachidonic acid secretion GO:0050482 9.6 DRD4 DRD2
16 behavioral response to cocaine GO:0048148 9.58 DRD4 DRD2
17 response to iron ion GO:0010039 9.58 SLC6A3 DRD2
18 negative regulation of protein secretion GO:0050709 9.57 DRD4 DRD2
19 dopamine receptor signaling pathway GO:0007212 9.56 DRD4 DRD2
20 prepulse inhibition GO:0060134 9.55 SLC6A3 DRD2
21 dopamine metabolic process GO:0042417 9.54 DRD4 DRD2
22 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.5 OPRM1 OPRD1 DRD4
23 regulation of dopamine metabolic process GO:0042053 9.49 SLC6A3 DRD4
24 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.48 DRD4 DRD2
25 opioid receptor signaling pathway GO:0038003 9.43 OPRM1 OPRD1
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.4 DRD4 DRD2
27 adenohypophysis development GO:0021984 9.37 SLC6A3 DRD2
28 response to histamine GO:0034776 9.26 DRD4 DRD2
29 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.16 DRD4 DRD2
30 response to cocaine GO:0042220 9.13 SLC6A3 OPRM1 DRD2
31 behavioral response to ethanol GO:0048149 8.8 OPRM1 DRD4 DRD2

Molecular functions related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.71 OPRM1 OPRD1 DRD4 DRD2
2 neuropeptide binding GO:0042923 9.37 OPRM1 OPRD1
3 drug binding GO:0008144 9.33 SLC6A3 DRD4 DRD2
4 opioid receptor activity GO:0004985 9.32 OPRM1 OPRD1
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD4 DRD2
6 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD4 DRD2
7 dopamine binding GO:0035240 8.8 SLC6A3 DRD4 DRD2

Sources for Heroin Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....